---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-209253"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:27:44.128518+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Acadia Q1 revenue $268M (+10% YoY); DAYBUE sales $101M (+20%); reaffirms guidance

## Summary
- Total Q1 revenues $268M (+10% GAAP YoY, +11% adj); NUPLAZID $167M (+5% GAAP, +6% adj); DAYBUE $101M (+20%).
- DAYBUE STIX launch underway; ~30% of STIX patients treatment-naive or returning after liquid discontinuation.
- Phase 2 remlifanserin topline data in Alzheimer's disease psychosis expected Aug–Oct 2026, on track.
- Trofinetide Japan trial results anticipated Sep–Nov 2026; Delphi panel recommends DAYBUE as Rett syndrome standard of care.
- Reaffirms full-year 2026 financial guidance (no specific numbers provided).

## SEC filing metadata
- accession: 0001193125-26-209253
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/0001193125-26-209253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-209253
- JSON: https://secwatch.observer/filing/0001193125-26-209253.json
- Plain text: https://secwatch.observer/filing/0001193125-26-209253.txt

## Source-grounded claims
- claim_id: f34480a9bcabee2d21dbfcfada6ae6f10a16177a
  claim: ACADIA PHARMACEUTICALS INC reported the first quarter ended March 31, 2026 results: revenue total revenues of $268 million. Guidance reaffirmed.
  evidence_excerpt: Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/0001193125-26-209253-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.